The fight against COVID19
23.64k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
Performance
| Watchlist | Change today | 1-month return | 1-year return | Total return |
|---|---|---|---|---|
| The fight against COVID19 | -1.78% | - | - | - |
| ^GSPC | -1.11% | +5.80% | -10.23% | +4327.81% |
14 symbols
| Symbol | Company name | Last price | Change | % change | Market time | Volume | Avg vol (3-month) | Market cap |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 163.61 | +0.21 | +0.13% | 4:00 pm GMT-5 | 6.04M | 7.11M | 427.76B |
| ABBV | AbbVie Inc. | 144.61 | -0.53 | -0.37% | 4:03 pm GMT-5 | 5.64M | 5.50M | 255.74B |
| PFE | Pfizer Inc. | 43.98 | +0.39 | +0.89% | 4:03 pm GMT-5 | 19.27M | 22.20M | 246.87B |
| SNY | Sanofi | 47.71 | +0.74 | +1.58% | 4:00 pm GMT-5 | 2.26M | 2.51M | 119.53B |
| GILD | Gilead Sciences, Inc. | 85.67 | -0.38 | -0.44% | 4:00 pm GMT-5 | 7.02M | 7.29M | 106.83B |
| REGN | Regeneron Pharmaceuticals, Inc. | 749.66 | -20.28 | -2.63% | 4:00 pm GMT-5 | 617.66k | 651.99k | 81.96B |
| GSK | GSK plc | 36.32 | +0.15 | +0.41% | 4:00 pm GMT-5 | 3.40M | 5.05M | 74.36B |
| MRNA | Moderna, Inc. | 164.34 | -6.72 | -3.93% | 4:00 pm GMT-5 | 2.81M | 5.00M | 63.14B |
| TAK | Takeda Pharmaceutical Company Limited | 16.12 | +0.20 | +1.26% | 4:00 pm GMT-5 | 2.32M | 2.84M | 50.31B |
| BNTX | BioNTech SE | 141.15 | -0.97 | -0.68% | 4:00 pm GMT-5 | 627.10k | 893.58k | 34.25B |
| VIR | Vir Biotechnology, Inc. | 27.07 | -2.38 | -8.08% | 4:00 pm GMT-5 | 940.96k | 795.61k | 3.60B |
| NVAX | Novavax, Inc. | 10.44 | -0.45 | -4.13% | 4:00 pm GMT-5 | 4.08M | 6.98M | 887.44M |
| INO | Inovio Pharmaceuticals, Inc. | 1.675 | -0.19 | -9.95% | 4:00 pm GMT-5 | 4.70M | 5.39M | 417.89M |
- GlobeNewswire
EYLEA® (aflibercept) Injection Approved as the First Pharmacologic Treatment for Preterm Infants with Retinopathy of Prematurity (ROP) by the FDA
ROP is a leading cause of childhood blindness worldwide EYLEA now approved to treat five retinal conditions caused by ocular angiogenesis TARRYTOWN, N.Y., Feb. 08, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA® (aflibercept) Injection to treat preterm infants with retinopathy of prematurity (ROP). Following this first pediatric approval, EYLEA is now indicated to treat five retinal condi
- Business Wire
Takeda Completes Acquisition of Nimbus Therapeutics’ TYK2 Program Subsidiary
OSAKA, Japan & CAMBRIDGE, Mass., February 08, 2023--Takeda today announced that it has completed an acquisition of all shares of Nimbus Lakshmi, Inc. from Nimbus Therapeutics, LLC
- Zacks
BioNTech SE Sponsored ADR (BNTX) Stock Moves -0.68%: What You Should Know
In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $141.15, marking a -0.68% move from the previous day.
